Seae Ventures
Seae Ventures, established in 2019 and headquartered in Boston, Massachusetts, is a venture capital firm specializing in early-stage and growth capital investments. The firm focuses on healthcare technology and services, with a commitment to investing in minority and women-owned companies, particularly those led by women and BIPOC individuals. Seae Ventures aims to generate financial returns by supporting entrepreneurs who deliver superior value, targeting sectors such as women's health, mental health, information technology, and personalized medicine, with a focus on benefiting traditionally underserved and vulnerable populations.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in South Carolina
Kiyatec
Series C in 2022
Kiyatec, LLC is a biotechnology company specializing in the development of advanced 3D cell-based assays aimed at enhancing preclinical drug discovery and clinical therapy applications. Founded in 2005 and based in Greenville, South Carolina, Kiyatec employs its proprietary 3DKUBE technology platform to create functional 3D models using patients' own living tumor cells. This innovative approach allows for the evaluation of various cancer therapies, providing insights into drug toxicity and efficacy before clinical trials. The company offers a range of services, including drug response profiling, predictions of patient responses to therapies, and cell-based assays for oncologists. Additionally, Kiyatec collaborates with biopharma clients on standard and custom assays and conducts research funded by the National Cancer Institute to develop 3D cell culture models for several types of cancer, such as breast cancer, glioblastoma, and lung cancer. By modeling complex human biology and simulating in vivo conditions, Kiyatec aims to improve treatment selection for cancer patients and support the development of medical devices and therapeutic drugs.
Kiyatec
Venture Round in 2021
Kiyatec, LLC is a biotechnology company specializing in the development of advanced 3D cell-based assays aimed at enhancing preclinical drug discovery and clinical therapy applications. Founded in 2005 and based in Greenville, South Carolina, Kiyatec employs its proprietary 3DKUBE technology platform to create functional 3D models using patients' own living tumor cells. This innovative approach allows for the evaluation of various cancer therapies, providing insights into drug toxicity and efficacy before clinical trials. The company offers a range of services, including drug response profiling, predictions of patient responses to therapies, and cell-based assays for oncologists. Additionally, Kiyatec collaborates with biopharma clients on standard and custom assays and conducts research funded by the National Cancer Institute to develop 3D cell culture models for several types of cancer, such as breast cancer, glioblastoma, and lung cancer. By modeling complex human biology and simulating in vivo conditions, Kiyatec aims to improve treatment selection for cancer patients and support the development of medical devices and therapeutic drugs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.